troxerutina kern pharma 100 mg/ml solucion oral efg
kern pharma s.l. - troxerutina - soluciÓn oral - 100 mg/ml - troxerutina 100 mg - troxerutina
variliv troxerutina 1 g granulado para solucion oral
laboratorios cinfa s.a. - troxerutina - granulado para soluciÓn oral - 1.000 mg - troxerutina 1000 mg - troxerutina
troxerutina normon 100 mg/ml solucion oral efg
laboratorios normon, s.a. - troxerutina - excipientes: sacarina sodica,sorbato potasico,parahidroxibenzoato de metilo,parahidroxibenzoato de propilo,propilenglicol - agentes estabilizadores de capilares - bioflavoniodes - troxerutina
troxerutina normon 1000 mg granulado para solucion oral
laboratorios normon, s.a. - troxerutina - excipientes: sacarina sodica,isomalta - agentes estabilizadores de capilares - bioflavoniodes - troxerutina
troxerutina pensa 100 mg/ml solucion oral efg
pensa pharma, s.a.u - troxerutina - excipientes: propilenglicol,parahidroxibenzoato de metilo,parahidroxibenzoato de propilo,sorbato potasico,sacarina sodica - agentes estabilizadores de capilares - bioflavoniodes - troxerutina
esberiven 100 mg/ml solucion oral
faes farma s.a. - troxerutina - soluciÓn oral - 100 mg/ml - troxerutina 100 mg - troxerutina
venoruton 20 mg/g gel
glaxosmithkline consumer healthcare, s.a. - troxerutina - gel - 20 mg/g - troxerutina 20 mg - troxerutina
venoruton oxerutinas 1 g polvo para solucion oral
laboratorio stada s.l. - troxerutina - granulado para soluciÓn oral - 1.000 mg - troxerutina 1000 mg - troxerutina
jaypirca
eli lilly nederland b.v. - pirtobrutinib - linfoma, célula del manto - inhibidores de la proteína quinasa - treatment of mantle cell lymphoma (mcl).
imbruvica
janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.